Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Marinus Pharma CS
(NQ:
MRNS
)
0.3707
-0.0344 (-8.49%)
Streaming Delayed Price
Updated: 3:50 PM EDT, Oct 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,774,775
Open
0.3849
Bid (Size)
0.3706 (13)
Ask (Size)
0.3707 (9)
Prev. Close
0.4051
Today's Range
0.3451 - 0.4242
52wk Range
0.2603 - 11.26
Shares Outstanding
55,084,038
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Monday's Pre-Market Session
Today 8:07 EDT
Via
Benzinga
Crude Oil Down 1%; Dow Posts Upbeat Earnings
October 24, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Performance
YTD
-96.44%
-96.44%
1 Month
-79.85%
-79.85%
3 Month
-73.52%
-73.52%
6 Month
-73.52%
-73.52%
1 Year
-94.70%
-94.70%
More News
Read More
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
October 24, 2024
Via
Benzinga
Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results
October 24, 2024
Via
Benzinga
Dow Falls 150 Points; Tesla Posts Upbeat Earnings
October 24, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
October 24, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
October 17, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
October 15, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
October 11, 2024
Via
MarketBeat
Topics
ETFs
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
October 09, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 08, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
October 01, 2024
Via
MarketBeat
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
September 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
September 12, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
August 19, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024
August 13, 2024
Via
InvestorPlace
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
3 Biotech Stocks to Sell in August Before They Crash & Burn
August 06, 2024
Via
InvestorPlace
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
August 05, 2024
From
The Schall Law Firm
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Teradata, and Lamb Weston and Encourages Investors to Contact the Firm
August 02, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
August 02, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
August 02, 2024
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus
August 02, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
MRNS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS
August 02, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.